Adjunctive Cannabidiol for Pharmaco-Resistant Lennox–Gastaut Syndrome in an Adult with Learning Disability

Lennox–Gastaut Syndrome (LGS) is an epilepsy syndrome with childhood onset that persists into adulthood. LGS is characterised by multiple seizure types, cognitive impairment, and behavioural presentations. Around 33% of individuals have normal intellect prior to seizure onset, but subsequent diagnosis of intellectual disability is evident in most individuals. Most individuals experience treatment-resistant seizures and significant functional impairments for the duration of life. Epidyolex (cannabidiol) is a novel, licensed adjunctive therapy for seizures associated with LGS and has orphan drug status. This case study presents the outcomes from a 36-year-old woman with pharmaco-resistant LGS, intellectual disability, and non-verbal communication following introduction of Epidyolex. Drawing upon current evidence and UK clinical guidance, the report explores pharmacological strategies, holistic interventions, and long-term management considerations. The case highlights the importance of multidisciplinary coordination, personalized care planning, and regular treatment evaluation in improving outcomes for adults living with complex epilepsy syndromes.